November 9, 2023- On Nov. 2, 2023, Cleveland Clinic Lou Ruvo Center for Brain Health marked a milestone in Alzheimer’s disease care by administering its first infusion of the anti-amyloid drug, lecanemab (LEQEMBI®), for the treatment of mild Alzheimer’s disease.
In conjunction with National Alzheimer’s Disease Awareness Month, the Lou Ruvo Center for Brain Health in Las Vegas administered its first dose of lecanemab in a clinical setting following the drug’s traditional approval from the U.S. Food and Drug Administration in July.
As one of the leading and largest Alzheimer’s disease clinical trial sites in the country, the Lou Ruvo Center for Brain Health has taken part in the phase 3 CLARITY study of lecanemab since 2020 and continues to study the drug in the ongoing AHEAD trial for individuals at risk for dementia. The center is the only site for both studies in the state of Nevada.
Dan Harrington, a 64 year old living with Alzheimer’s disease, is originally from southern California and moved to Las Vegas six years ago specifically to receive care at the Lou Ruvo Center for Brain Health. He and his wife, Andrea, are grateful to have the opportunity to try this new treatment.